Anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome
Open Access
- 1 May 2005
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 64 (5) , 791-792
- https://doi.org/10.1136/ard.2004.029603
Abstract
In these situations, specific antibodies may be useful for making a correct diagnosis and, consequently, guide treatment. Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been shown to be a specific marker for the diagnosis of RA.2 They bind to determinants rich in the unusual amino acid, citrulline, generated by deamination of arginine.3 We have read the recent article by Gottenberg et al,4 in which a 7.5% prevalence of anti-CCP antibodies in 134 French patients with pSS was reported. Here, we describe a similar experience in Colombian patients with pSS.Keywords
This publication has 7 references indexed in Scilit:
- Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2005
- Anticuerpos anti-CCP en artritis reumatoidea: relación con características clínicas, citocinas Th1/Th2 y HLA-DRB1.Biomédica, 2004
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- Diagnostic Accuracy of the Anti-Citrulline Antibody Assay for Rheumatoid ArthritisClinical Chemistry, 2001
- The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptideArthritis & Rheumatism, 2000
- Sjögren's syndrome comes of ageSeminars in Arthritis and Rheumatism, 1999
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988